1209459-10-8 Usage
Uses
Used in Pharmaceutical Industry:
2-Bromo-5-fluoropyrazine is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications. Its unique structure allows for the creation of diverse chemical compounds with valuable properties, enhancing the range of available medications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-5-fluoropyrazine serves as a key component in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these products helps improve their effectiveness in controlling pests and weeds, thereby increasing crop yields and ensuring food security.
Used as a Reagent in Organic Synthesis:
2-Bromo-5-fluoropyrazine is utilized as a reagent in organic synthesis, particularly for the creation of new chemical compounds with desirable properties. Its unique reactivity enables the formation of a wide range of important chemical products, expanding the scope of chemical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 1209459-10-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,9,4,5 and 9 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1209459-10:
(9*1)+(8*2)+(7*0)+(6*9)+(5*4)+(4*5)+(3*9)+(2*1)+(1*0)=148
148 % 10 = 8
So 1209459-10-8 is a valid CAS Registry Number.
1209459-10-8Relevant academic research and scientific papers
Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
-
Page 150, (2010/02/10)
This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.
